|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
2010-8-3
|
|
pubmed:abstractText |
We report the concentrations of maraviroc in the cerebrospinal fluid (CSF) and plasma of six HIV-1-infected patients with both neurological impairment and detectable HIV-1 replication in CSF. One month after starting maraviroc, the viral load in the CSF decreased significantly (P = 0.005). The median (range) maraviroc concentration in plasma was 347 ng/ml (123-2678). Four patients had CSF concentrations above the protein-adjusted inhibitory concentration (IC90) of 0.57 ng/ml (0.06-10.7) with a median of 102 ng/ml (35-173).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1473-5571
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
24
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2130-3
|
|
pubmed:meshHeading |
pubmed-meshheading:20601852-Adult,
pubmed-meshheading:20601852-Anti-HIV Agents,
pubmed-meshheading:20601852-Central Nervous System Diseases,
pubmed-meshheading:20601852-Cyclohexanes,
pubmed-meshheading:20601852-Female,
pubmed-meshheading:20601852-HIV Infections,
pubmed-meshheading:20601852-HIV-1,
pubmed-meshheading:20601852-Humans,
pubmed-meshheading:20601852-Male,
pubmed-meshheading:20601852-Middle Aged,
pubmed-meshheading:20601852-Triazoles
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms.
|
|
pubmed:affiliation |
Department of Clinical Immunology, Henri Mondor Hospital, Université Paris XII Creteil, Creteil, France. giovanna.melica@hmn.aphp.fr
|
|
pubmed:publicationType |
Journal Article
|
